Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PDS Biotechnology ( (PDSB) ) has issued an announcement.
On February 20, 2026, PDS Biotechnology adopted an amended protocol for its Phase 3 VERSATILE-003 trial of PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer, adding progression-free survival as an interim primary endpoint to support a potential accelerated approval pathway. Median overall survival remains the primary endpoint for full approval, and following the FDA’s 30-day review period without objection, the company is proceeding under the new design, which it expects to shorten trial duration and improve cost efficiency while maintaining survival and safety as the basis for full regulatory clearance.
The most recent analyst rating on (PDSB) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.
Spark’s Take on PDSB Stock
According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.
The score is held down primarily by weak financial performance (no revenue, persistent losses/cash burn, and a diminished equity base), which raises financing risk. Technicals are neutral with only mild signs of improvement, while positive trial/regulatory progress and recent patents/clinical updates provide some offset. Valuation support is limited because losses make the P/E not meaningful and no dividend yield is available.
To see Spark’s full report on PDSB stock, click here.
More about PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company is advancing its lead investigational targeted immunotherapy PDS0101 (Versamune® HPV) for advanced HPV16-positive head and neck squamous cell cancers, including in combinations with standard-of-care immune checkpoint inhibitors and its IL-12 fused antibody drug conjugate PDS01ADC.
Average Trading Volume: 660,371
Technical Sentiment Signal: Strong Sell
Current Market Cap: $36.71M
Find detailed analytics on PDSB stock on TipRanks’ Stock Analysis page.